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Introduction
Juvenile localised scleroderma (JLS) is a rare condition.
Researchers and clinicians seeking to improve care for
children and young people (CYP) with JLS face various
challenges. JLS is often difficult to assess, both at disease
onset and as the condition progresses. A variety of mon-
itoring tools (mts) have been described for JLS.
Objectives
- To describe how mts are used and perceived by clini-
cians in the United Kingdom (UK).
- To describe treatments used for JLS in CYP.
Methods
We surveyed paediatric rheumatologists (prs) and der-
matologists (dms) in the UK who manage CYP with JLS,
via an an e-survey distributed to the membership of two
national organisations representing these clinician
groups. We asked respondents for their views and
experience using 15 distinct JLS mts; about transition
services and treatments used.
Results
48 clinicians (35 dms, 13 prs) from across the UK
responded. At time of survey response, dms reported
managing a mean 4.2 CYP with JLS; prs 17.9. 26% dms
managed all CYP in collaboration (with a PR, paediatri-
cian, adult rheumatologist or another DM) whilst 31%
prs managed all CYP in collaboration (with a DM or
paediatrician). 43% of dms and 91% prs reported formal
transition arrangements. 9% dms and 69% prs reported
involving an adult rheumatologist in transition; 8% prs
involved a DM in transition.
Medical photography (100%), thermography (67%) and
drawing in notes/use of pre-printed body map (both
56%) were the most regularly used mts by prs; photogra-
phy (81%) drawing in notes (56%) and ultrasound (22%)
were most regularly used by dms. Of 4 skin scores, the
modified Rodnan skin score was the one clinicians used
most frequently. However it was only used regularly by
33% prs and 3% dms. Familiarity, use (frequently or
occasionally) and perceived benefit of all other skin
scores was low (0-40%). Laser doppler imaging, laser
doppler flowmetry and 3.0T MRI were perceived useful
by larger proportions (15-70%) of clinicians than reported
using them (either occasionally (0-60%) or regularly
(0-11%)).
Table 1 shows reported use of specific treatments for
JLS by clinician group.
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Table 1 Shows reported use of specific treatments for JLS
by clinician group
Treatment Used Reported use by prs
(% of respondents)
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Conclusion
A wide range of mts are used in the UK by prs and dms
managing CYP with JLS. How these tools are accessed,
used and perceived varies between and within these
clinician groups. There are also differences in prescribing
of treatments between prs and dms. These differences
will impact on the feasibility of conducting clinical trials
in JLS. Further work is needed to determine accessible
and validated mts for CYP with JLS. Collaboration
between dms and prs is an important factor in facilitating
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